Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Debt to Equity (2016 - 2025)

Adma Biologics (ADMA) has disclosed Debt to Equity for 12 consecutive years, with $0.15 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity fell 27.08% year-over-year to $0.15, compared with a TTM value of $0.15 through Dec 2025, down 27.08%, and an annual FY2025 reading of $0.15, down 27.08% over the prior year.
  • Debt to Equity was $0.15 for Q4 2025 at Adma Biologics, down from $0.17 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.41 in Q3 2022 and bottomed at $0.15 in Q4 2025.
  • Average Debt to Equity over 5 years is $0.73, with a median of $0.85 recorded in 2021.
  • The sharpest move saw Debt to Equity surged 436.23% in 2021, then tumbled 78.54% in 2024.
  • Year by year, Debt to Equity stood at $0.67 in 2021, then skyrocketed by 39.86% to $0.94 in 2022, then increased by 2.77% to $0.97 in 2023, then crashed by 78.54% to $0.21 in 2024, then dropped by 27.08% to $0.15 in 2025.
  • Business Quant data shows Debt to Equity for ADMA at $0.15 in Q4 2025, $0.17 in Q3 2025, and $0.18 in Q2 2025.